Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585803 | 0.86 | LMNA (0.46) | SMN1; SMN2SIGMAR1LMNACA1CA2 | |
| SCHEMBL2918641 | 0.83 | IDO1 (0.48) | PPARGSIGMAR1LMNAIDO1 | |
| SCHEMBL196102 | 0.83 | RAB9A (0.44) | PTGESALOX5PPARGSMN1; SMN2CTSK | |
| SCHEMBL3506182 | 0.80 | MEN1 (0.44) | PTGESALOX5PPARGSMN1; SMN2SIGMAR1 | |
| SCHEMBL6319500 | 0.80 | CHRM2 (0.44) | SIGMAR1IDO1 | |
| SCHEMBL4449191 | 0.79 | CA1 (0.44) | SIGMAR1CA1CA2CA9IDO1 | |
| SCHEMBL7404908 | 0.79 | CA1 (0.38) | PTGESALOX5PPARGSMN1; SMN2SIGMAR1 | |
| SCHEMBL27987850 | 0.78 | MEN1 (0.42) | SIGMAR1CA1CA2CA9IDO1 | |
| SCHEMBL449609 | 0.78 | LMNA (0.52) | SMN1; SMN2SIGMAR1LMNA | |
| SCHEMBL2775072 | 0.77 | CA1 (0.34) | PTGESALOX5PPARGSMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| US-5972864-A | BLEACHING BLOCK; MIXTURE OF BLEACH AND ORGANOLEPTIC COMPOUND | LONZA INC. (US) | 1999-10-26 | — | — | US | claimed |
| US-5942153-A | A SHAPED STABLE BLOCK COMPRISING AN ORGANOLEPTIC FRAGRANT AGENT AND BLEACHING AGENT; FRAGRANT AGENT DOES NOT DECOMPOSE THE BLEACHING AGENT, NOT HYGROSCOPIC; USE IN VENTILATING HOOD AS PROTECTIVE GLOVES, A DUST MASK, AND GOGGLES | BUSH BOAKE ALLEN INC. (US) | 1999-08-24 | — | — | US | claimed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | NOVABAY PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | disclosed |
| US-6255268-B1 | CONTAINING 1,3-DICHLORO-5,5-DIMETHYLHYDANTOIN AND ORGANOLEPTIC AGENT | LONZA INC. | 2001-07-03 | — | — | US | disclosed |
| EP-0966517-A1 | BLEACHING AND CLEANING COMPOSITIONS CONTAINING FRAGRANCES | LONZA INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5972864-A | BLEACHING BLOCK; MIXTURE OF BLEACH AND ORGANOLEPTIC COMPOUND | LONZA INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5942153-A | A SHAPED STABLE BLOCK COMPRISING AN ORGANOLEPTIC FRAGRANT AGENT AND BLEACHING AGENT; FRAGRANT AGENT DOES NOT DECOMPOSE THE BLEACHING AGENT, NOT HYGROSCOPIC; USE IN VENTILATING HOOD AS PROTECTIVE GLOVES, A DUST MASK, AND GOGGLES | BUSH BOAKE ALLEN INC. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998036049-A1 | BLEACHING AND CLEANING COMPOSITIONS CONTAINING FRAGRANCES | LONZA INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | PTGES 1029/4885ALOX5 1045/4885PPARG 1807/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | PTGES 1029/4885ALOX5 1045/4885PPARG 1807/4885 |
| US-20110190392-A1 | Polysaccharide Based Antimicrobial Formulations | FUT6, FUT5, OGT | PTGES 4411/4885ALOX5 2411/4885PPARG 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.